title: Intergenic region 3 of modified vaccinia ankara is a functional site for insert gene expression and allows for potent antigen-specific immune responses.
abstract: Integration of exogenous DNA into modified vaccinia Ankara (MVA) is often accomplished using mapped deletion sites in the viral genome. Since MVA has a large capacity (> or =30kb) for foreign gene inserts and a limited number of unique integration sites, development of additional integration sites is needed to take full advantage of the extraordinary capacity for foreign gene insertion. In this report, we evaluate an alternative insertion site known as intergenic region 3 (IGR3). Recombinant MVA carrying the cytomegalovirus pp65 gene in IGR3 (rMVA-pp65-IGR3) demonstrated expression and genetic stability of the insert gene upon passage. Immunization of transgenic HLA-A2 mice with rMVA-pp65-IGR3 induced robust antigen-specific immune responses. Moreover, rMVA-pp65-IGR3-infected human EBV-transformed B cell lines were able to stimulate high levels of pp65-specific memory T cell responses in human PBMCs. These data support the usage of IGR3 for the development of highly immunogenic rMVA vaccines for clinical or veterinary use.
authors.affiliation: Beckman Research Institute of the City of Hope, Duarte, CA 91010, USA.
authors.forename: Edwin R
authors.initials: ER
authors.lastname: Manuel
authors.forename: Zhongde
authors.initials: Z
authors.lastname: Wang
authors.forename: Zhongqi
authors.initials: Z
authors.lastname: Li
authors.forename: Corinna
authors.initials: C
authors.lastname: La Rosa
authors.forename: Wendi
authors.initials: W
authors.lastname: Zhou
authors.forename: Don J
authors.initials: DJ
authors.lastname: Diamond
mesh_terms: D000818:Animals; D000941:Antigens / Q000235:genetics / Q000276:immunology*; D002460:Cell Line; D003587:Cytomegalovirus / Q000235:genetics / Q000276:immunology; D022482:Cytomegalovirus Vaccines / Q000235:genetics / Q000276:immunology; D021901:DNA, Intergenic; D015870:Gene Expression; D005818:Genetic Engineering; D005822:Genetic Vectors; D006801:Humans; D051379:Mice; D008822:Mice, Transgenic; D013601:T-Lymphocytes / Q000276:immunology; D014614:Vaccines, Synthetic / Q000235:genetics / Q000276:immunology; D014616:Vaccinia virus / Q000235:genetics*
chemical_list: D000941:Antigens; D022482:Cytomegalovirus Vaccines; D021901:DNA, Intergenic; D014614:Vaccines, Synthetic
references.citation: J Gen Virol. 2005 Nov;86(Pt 11):2925-2936
references.pmid: 16227213
references.citation: Cancer Res. 2003 Nov 15;63(22):7942-9
references.pmid: 14633725
references.citation: Virology. 2008 Aug 1;377(2):379-90
references.pmid: 18538366
references.citation: Vaccine. 2006 May 22;24(21):4618-21
references.pmid: 16157428
references.citation: Cancer Immunol Immunother. 2000 Jun;49(3):123-32
references.pmid: 10881691
references.citation: Dev Biol Stand. 1978;41:225-34
references.pmid: 223909
references.citation: Curr Gene Ther. 2008 Apr;8(2):97-120
references.pmid: 18393831
references.citation: Hepatology. 2001 Aug;34(2):372-6
references.pmid: 11481622
references.citation: J Gen Virol. 1991 May;72 ( Pt 5):1031-8
references.pmid: 2033387
references.citation: Mol Cell Biol. 1985 Dec;5(12):3403-9
references.pmid: 3939316
references.citation: Nat Med. 2007 Jan;13(1):100-6
references.pmid: 17187074
references.citation: J Exp Med. 1997 Jun 16;185(12):2043-51
references.pmid: 9182675
references.citation: Med Microbiol Immunol. 2008 Jun;197(2):117-23
references.pmid: 18196272
references.citation: Vaccine. 2007 Jan 22;25(6):1132-41
references.pmid: 17049414
references.citation: Vaccine. 2010 Feb 10;28(6):1547-57
references.pmid: 19969118
references.citation: Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8
references.pmid: 8876137
references.citation: Virology. 2007 Sep 15;366(1):84-97
references.pmid: 17499326
references.citation: J Med Virol. 1994 May;43(1):103-10
references.pmid: 8083644
references.citation: Curr Opin Biotechnol. 2004 Dec;15(6):506-12
references.pmid: 15560976
references.citation: Virology. 2008 Mar 15;372(2):260-72
references.pmid: 18048074
references.citation: J Gen Virol. 1998 Feb;79 ( Pt 2):347-52
references.pmid: 9472619
references.citation: Exp Hematol. 2006 Apr;34(4):497-507
references.pmid: 16569596
references.citation: Blood. 2004 Aug 1;104(3):847-56
references.pmid: 15090456
references.citation: Gene. 1996 Jun 26;172(2):233-7
references.pmid: 8682309
references.citation: Vaccine. 2009 Sep 25;27(42):5885-95
references.pmid: 19654066
references.citation: Blood. 1997 Sep 1;90(5):1751-67
references.pmid: 9292508
references.citation: Immunol Lett. 2008 Oct 30;120(1-2):108-16
references.pmid: 18706443
references.citation: Vaccine. 2007 Apr 12;25(15):2863-85
references.pmid: 17113200
references.citation: J Virol. 2004 Apr;78(8):3965-76
references.pmid: 15047812
references.citation: J Clin Virol. 2006 Mar;35(3):324-31
references.pmid: 16388983
references.citation: J Virol. 2004 Apr;78(7):3333-42
references.pmid: 15016855
references.citation: Nat Biotechnol. 2002 Jan;20(1):87-90
references.pmid: 11753368
references.citation: J Immunol. 1991 Sep 1;147(5):1512-21
references.pmid: 1715361
references.citation: Cancer Immunol Immunother. 2005 May;54(5):453-67
references.pmid: 15627214
references.citation: J Immunother. 2009 Sep;32(7):765-72
references.pmid: 19561532
references.citation: J Virol. 1996 Nov;70(11):7569-79
references.pmid: 8892876
references.citation: AIDS Res Hum Retroviruses. 2008 Feb;24(2):195-206
references.pmid: 18240957
references.citation: J Virol. 1994 Jan;68(1):130-47
references.pmid: 8254722
references.citation: Acta Virol. 2001;45(4):243-7
references.pmid: 11885931
references.citation: J Virol. 1998 Apr;72(4):2917-26
references.pmid: 9525612
references.citation: J Virol. 2000 Jan;74(2):923-33
references.pmid: 10623755
references.citation: J Virol. 2009 Jul;83(14):7176-84
references.pmid: 19420086